nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—CYP2C9—Ifosfamide—testicular cancer	0.0811	0.352	CbGbCtD
Bexarotene—CYP3A4—Ifosfamide—testicular cancer	0.0471	0.204	CbGbCtD
Bexarotene—CYP2C9—Cisplatin—testicular cancer	0.0394	0.171	CbGbCtD
Bexarotene—CYP3A4—Vinblastine—testicular cancer	0.025	0.108	CbGbCtD
Bexarotene—CYP3A4—Etoposide—testicular cancer	0.0225	0.0977	CbGbCtD
Bexarotene—CYP3A4—Doxorubicin—testicular cancer	0.0154	0.0667	CbGbCtD
Bexarotene—Urinary tract disorder—Methotrexate—testicular cancer	0.00039	0.000506	CcSEcCtD
Bexarotene—Photosensitivity reaction—Doxorubicin—testicular cancer	0.00039	0.000506	CcSEcCtD
Bexarotene—Weight increased—Doxorubicin—testicular cancer	0.000388	0.000505	CcSEcCtD
Bexarotene—Epistaxis—Epirubicin—testicular cancer	0.000388	0.000504	CcSEcCtD
Bexarotene—Urethral disorder—Methotrexate—testicular cancer	0.000387	0.000502	CcSEcCtD
Bexarotene—Weight decreased—Doxorubicin—testicular cancer	0.000386	0.000502	CcSEcCtD
Bexarotene—Sinusitis—Epirubicin—testicular cancer	0.000386	0.000501	CcSEcCtD
Bexarotene—Feeling abnormal—Etoposide—testicular cancer	0.000386	0.000501	CcSEcCtD
Bexarotene—Hyperglycaemia—Doxorubicin—testicular cancer	0.000385	0.0005	CcSEcCtD
Bexarotene—Nausea—Dactinomycin—testicular cancer	0.000384	0.000499	CcSEcCtD
Bexarotene—Pneumonia—Doxorubicin—testicular cancer	0.000383	0.000497	CcSEcCtD
Bexarotene—Gastrointestinal pain—Etoposide—testicular cancer	0.000383	0.000497	CcSEcCtD
Bexarotene—Vomiting—Ifosfamide—testicular cancer	0.000377	0.000489	CcSEcCtD
Bexarotene—Hypersensitivity—Cisplatin—testicular cancer	0.000376	0.000489	CcSEcCtD
Bexarotene—Rash—Ifosfamide—testicular cancer	0.000374	0.000485	CcSEcCtD
Bexarotene—Dermatitis—Ifosfamide—testicular cancer	0.000373	0.000485	CcSEcCtD
Bexarotene—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000373	0.000485	CcSEcCtD
Bexarotene—Haemoglobin—Epirubicin—testicular cancer	0.000371	0.000482	CcSEcCtD
Bexarotene—Stomatitis—Doxorubicin—testicular cancer	0.000371	0.000482	CcSEcCtD
Bexarotene—Jaundice—Doxorubicin—testicular cancer	0.000371	0.000482	CcSEcCtD
Bexarotene—Rhinitis—Epirubicin—testicular cancer	0.00037	0.000481	CcSEcCtD
Bexarotene—Abdominal pain—Etoposide—testicular cancer	0.00037	0.000481	CcSEcCtD
Bexarotene—Body temperature increased—Etoposide—testicular cancer	0.00037	0.000481	CcSEcCtD
Bexarotene—Conjunctivitis—Doxorubicin—testicular cancer	0.00037	0.000481	CcSEcCtD
Bexarotene—Urinary tract infection—Doxorubicin—testicular cancer	0.00037	0.000481	CcSEcCtD
Bexarotene—Haemorrhage—Epirubicin—testicular cancer	0.000369	0.00048	CcSEcCtD
Bexarotene—Eye disorder—Methotrexate—testicular cancer	0.000369	0.000479	CcSEcCtD
Bexarotene—Tinnitus—Methotrexate—testicular cancer	0.000368	0.000478	CcSEcCtD
Bexarotene—Hypoaesthesia—Epirubicin—testicular cancer	0.000367	0.000477	CcSEcCtD
Bexarotene—Asthenia—Cisplatin—testicular cancer	0.000366	0.000476	CcSEcCtD
Bexarotene—Pharyngitis—Epirubicin—testicular cancer	0.000366	0.000476	CcSEcCtD
Bexarotene—Cardiac disorder—Methotrexate—testicular cancer	0.000366	0.000476	CcSEcCtD
Bexarotene—Sweating—Doxorubicin—testicular cancer	0.000365	0.000474	CcSEcCtD
Bexarotene—Urinary tract disorder—Epirubicin—testicular cancer	0.000365	0.000474	CcSEcCtD
Bexarotene—Oedema peripheral—Epirubicin—testicular cancer	0.000364	0.000473	CcSEcCtD
Bexarotene—Haematuria—Doxorubicin—testicular cancer	0.000363	0.000471	CcSEcCtD
Bexarotene—Connective tissue disorder—Epirubicin—testicular cancer	0.000363	0.000471	CcSEcCtD
Bexarotene—Urethral disorder—Epirubicin—testicular cancer	0.000362	0.00047	CcSEcCtD
Bexarotene—Epistaxis—Doxorubicin—testicular cancer	0.000359	0.000466	CcSEcCtD
Bexarotene—Angiopathy—Methotrexate—testicular cancer	0.000358	0.000465	CcSEcCtD
Bexarotene—Sinusitis—Doxorubicin—testicular cancer	0.000357	0.000464	CcSEcCtD
Bexarotene—Chills—Methotrexate—testicular cancer	0.000354	0.00046	CcSEcCtD
Bexarotene—Nausea—Ifosfamide—testicular cancer	0.000352	0.000457	CcSEcCtD
Bexarotene—Diarrhoea—Cisplatin—testicular cancer	0.000349	0.000454	CcSEcCtD
Bexarotene—Alopecia—Methotrexate—testicular cancer	0.000349	0.000453	CcSEcCtD
Bexarotene—Eye disorder—Epirubicin—testicular cancer	0.000345	0.000448	CcSEcCtD
Bexarotene—Hypersensitivity—Etoposide—testicular cancer	0.000345	0.000448	CcSEcCtD
Bexarotene—Tinnitus—Epirubicin—testicular cancer	0.000344	0.000447	CcSEcCtD
Bexarotene—Erythema—Methotrexate—testicular cancer	0.000343	0.000446	CcSEcCtD
Bexarotene—Malnutrition—Methotrexate—testicular cancer	0.000343	0.000446	CcSEcCtD
Bexarotene—Haemoglobin—Doxorubicin—testicular cancer	0.000343	0.000446	CcSEcCtD
Bexarotene—Cardiac disorder—Epirubicin—testicular cancer	0.000343	0.000445	CcSEcCtD
Bexarotene—Rhinitis—Doxorubicin—testicular cancer	0.000342	0.000445	CcSEcCtD
Bexarotene—Haemorrhage—Doxorubicin—testicular cancer	0.000342	0.000444	CcSEcCtD
Bexarotene—Hypoaesthesia—Doxorubicin—testicular cancer	0.00034	0.000442	CcSEcCtD
Bexarotene—Pharyngitis—Doxorubicin—testicular cancer	0.000339	0.000441	CcSEcCtD
Bexarotene—Urinary tract disorder—Doxorubicin—testicular cancer	0.000337	0.000438	CcSEcCtD
Bexarotene—Oedema peripheral—Doxorubicin—testicular cancer	0.000336	0.000437	CcSEcCtD
Bexarotene—Dysgeusia—Methotrexate—testicular cancer	0.000336	0.000437	CcSEcCtD
Bexarotene—Asthenia—Etoposide—testicular cancer	0.000336	0.000436	CcSEcCtD
Bexarotene—Connective tissue disorder—Doxorubicin—testicular cancer	0.000336	0.000436	CcSEcCtD
Bexarotene—Angiopathy—Epirubicin—testicular cancer	0.000335	0.000435	CcSEcCtD
Bexarotene—Urethral disorder—Doxorubicin—testicular cancer	0.000335	0.000435	CcSEcCtD
Bexarotene—Back pain—Methotrexate—testicular cancer	0.000332	0.000432	CcSEcCtD
Bexarotene—Chills—Epirubicin—testicular cancer	0.000331	0.00043	CcSEcCtD
Bexarotene—Pruritus—Etoposide—testicular cancer	0.000331	0.00043	CcSEcCtD
Bexarotene—Arrhythmia—Epirubicin—testicular cancer	0.00033	0.000429	CcSEcCtD
Bexarotene—Alopecia—Epirubicin—testicular cancer	0.000326	0.000424	CcSEcCtD
Bexarotene—Vomiting—Cisplatin—testicular cancer	0.000325	0.000422	CcSEcCtD
Bexarotene—Rash—Cisplatin—testicular cancer	0.000322	0.000418	CcSEcCtD
Bexarotene—Dermatitis—Cisplatin—testicular cancer	0.000322	0.000418	CcSEcCtD
Bexarotene—Malnutrition—Epirubicin—testicular cancer	0.000321	0.000418	CcSEcCtD
Bexarotene—Erythema—Epirubicin—testicular cancer	0.000321	0.000418	CcSEcCtD
Bexarotene—Diarrhoea—Etoposide—testicular cancer	0.00032	0.000416	CcSEcCtD
Bexarotene—Eye disorder—Doxorubicin—testicular cancer	0.000319	0.000415	CcSEcCtD
Bexarotene—Ill-defined disorder—Methotrexate—testicular cancer	0.000319	0.000414	CcSEcCtD
Bexarotene—Tinnitus—Doxorubicin—testicular cancer	0.000318	0.000414	CcSEcCtD
Bexarotene—Anaemia—Methotrexate—testicular cancer	0.000317	0.000412	CcSEcCtD
Bexarotene—Cardiac disorder—Doxorubicin—testicular cancer	0.000317	0.000412	CcSEcCtD
Bexarotene—Flatulence—Epirubicin—testicular cancer	0.000317	0.000412	CcSEcCtD
Bexarotene—Tension—Epirubicin—testicular cancer	0.000315	0.00041	CcSEcCtD
Bexarotene—Dysgeusia—Epirubicin—testicular cancer	0.000315	0.000409	CcSEcCtD
Bexarotene—Nervousness—Epirubicin—testicular cancer	0.000312	0.000406	CcSEcCtD
Bexarotene—Back pain—Epirubicin—testicular cancer	0.000311	0.000404	CcSEcCtD
Bexarotene—Angiopathy—Doxorubicin—testicular cancer	0.00031	0.000403	CcSEcCtD
Bexarotene—Malaise—Methotrexate—testicular cancer	0.00031	0.000402	CcSEcCtD
Bexarotene—Dizziness—Etoposide—testicular cancer	0.000309	0.000402	CcSEcCtD
Bexarotene—Muscle spasms—Epirubicin—testicular cancer	0.000309	0.000401	CcSEcCtD
Bexarotene—Vertigo—Methotrexate—testicular cancer	0.000309	0.000401	CcSEcCtD
Bexarotene—Leukopenia—Methotrexate—testicular cancer	0.000307	0.000399	CcSEcCtD
Bexarotene—Chills—Doxorubicin—testicular cancer	0.000306	0.000398	CcSEcCtD
Bexarotene—Arrhythmia—Doxorubicin—testicular cancer	0.000305	0.000397	CcSEcCtD
Bexarotene—Nausea—Cisplatin—testicular cancer	0.000303	0.000394	CcSEcCtD
Bexarotene—Alopecia—Doxorubicin—testicular cancer	0.000302	0.000392	CcSEcCtD
Bexarotene—Cough—Methotrexate—testicular cancer	0.0003	0.000389	CcSEcCtD
Bexarotene—Ill-defined disorder—Epirubicin—testicular cancer	0.000298	0.000387	CcSEcCtD
Bexarotene—Vomiting—Etoposide—testicular cancer	0.000297	0.000387	CcSEcCtD
Bexarotene—Erythema—Doxorubicin—testicular cancer	0.000297	0.000386	CcSEcCtD
Bexarotene—Malnutrition—Doxorubicin—testicular cancer	0.000297	0.000386	CcSEcCtD
Bexarotene—Anaemia—Epirubicin—testicular cancer	0.000297	0.000386	CcSEcCtD
Bexarotene—Agitation—Epirubicin—testicular cancer	0.000295	0.000384	CcSEcCtD
Bexarotene—Rash—Etoposide—testicular cancer	0.000295	0.000383	CcSEcCtD
Bexarotene—Dermatitis—Etoposide—testicular cancer	0.000295	0.000383	CcSEcCtD
Bexarotene—Headache—Etoposide—testicular cancer	0.000293	0.000381	CcSEcCtD
Bexarotene—Flatulence—Doxorubicin—testicular cancer	0.000293	0.000381	CcSEcCtD
Bexarotene—Chest pain—Methotrexate—testicular cancer	0.000292	0.00038	CcSEcCtD
Bexarotene—Myalgia—Methotrexate—testicular cancer	0.000292	0.00038	CcSEcCtD
Bexarotene—Arthralgia—Methotrexate—testicular cancer	0.000292	0.00038	CcSEcCtD
Bexarotene—Tension—Doxorubicin—testicular cancer	0.000292	0.000379	CcSEcCtD
Bexarotene—Dysgeusia—Doxorubicin—testicular cancer	0.000291	0.000378	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00029	0.000377	CcSEcCtD
Bexarotene—Malaise—Epirubicin—testicular cancer	0.00029	0.000377	CcSEcCtD
Bexarotene—Discomfort—Methotrexate—testicular cancer	0.000289	0.000375	CcSEcCtD
Bexarotene—Nervousness—Doxorubicin—testicular cancer	0.000289	0.000375	CcSEcCtD
Bexarotene—Vertigo—Epirubicin—testicular cancer	0.000289	0.000375	CcSEcCtD
Bexarotene—Syncope—Epirubicin—testicular cancer	0.000288	0.000374	CcSEcCtD
Bexarotene—Leukopenia—Epirubicin—testicular cancer	0.000288	0.000374	CcSEcCtD
Bexarotene—Back pain—Doxorubicin—testicular cancer	0.000288	0.000374	CcSEcCtD
Bexarotene—Muscle spasms—Doxorubicin—testicular cancer	0.000286	0.000371	CcSEcCtD
Bexarotene—Palpitations—Epirubicin—testicular cancer	0.000284	0.000369	CcSEcCtD
Bexarotene—Confusional state—Methotrexate—testicular cancer	0.000283	0.000367	CcSEcCtD
Bexarotene—Loss of consciousness—Epirubicin—testicular cancer	0.000282	0.000367	CcSEcCtD
Bexarotene—Cough—Epirubicin—testicular cancer	0.00028	0.000364	CcSEcCtD
Bexarotene—Infection—Methotrexate—testicular cancer	0.000278	0.000362	CcSEcCtD
Bexarotene—Nausea—Etoposide—testicular cancer	0.000278	0.000361	CcSEcCtD
Bexarotene—Hypertension—Epirubicin—testicular cancer	0.000277	0.000361	CcSEcCtD
Bexarotene—Ill-defined disorder—Doxorubicin—testicular cancer	0.000276	0.000359	CcSEcCtD
Bexarotene—Nervous system disorder—Methotrexate—testicular cancer	0.000275	0.000357	CcSEcCtD
Bexarotene—Anaemia—Doxorubicin—testicular cancer	0.000275	0.000357	CcSEcCtD
Bexarotene—Thrombocytopenia—Methotrexate—testicular cancer	0.000274	0.000357	CcSEcCtD
Bexarotene—Chest pain—Epirubicin—testicular cancer	0.000274	0.000356	CcSEcCtD
Bexarotene—Arthralgia—Epirubicin—testicular cancer	0.000274	0.000356	CcSEcCtD
Bexarotene—Myalgia—Epirubicin—testicular cancer	0.000274	0.000356	CcSEcCtD
Bexarotene—Agitation—Doxorubicin—testicular cancer	0.000273	0.000355	CcSEcCtD
Bexarotene—Anxiety—Epirubicin—testicular cancer	0.000273	0.000354	CcSEcCtD
Bexarotene—Skin disorder—Methotrexate—testicular cancer	0.000272	0.000354	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000272	0.000353	CcSEcCtD
Bexarotene—Hyperhidrosis—Methotrexate—testicular cancer	0.000271	0.000352	CcSEcCtD
Bexarotene—Discomfort—Epirubicin—testicular cancer	0.00027	0.000351	CcSEcCtD
Bexarotene—Malaise—Doxorubicin—testicular cancer	0.000268	0.000348	CcSEcCtD
Bexarotene—Dry mouth—Epirubicin—testicular cancer	0.000268	0.000348	CcSEcCtD
Bexarotene—Vertigo—Doxorubicin—testicular cancer	0.000267	0.000347	CcSEcCtD
Bexarotene—Anorexia—Methotrexate—testicular cancer	0.000267	0.000347	CcSEcCtD
Bexarotene—Syncope—Doxorubicin—testicular cancer	0.000267	0.000347	CcSEcCtD
Bexarotene—Leukopenia—Doxorubicin—testicular cancer	0.000266	0.000346	CcSEcCtD
Bexarotene—Confusional state—Epirubicin—testicular cancer	0.000264	0.000344	CcSEcCtD
Bexarotene—Palpitations—Doxorubicin—testicular cancer	0.000263	0.000341	CcSEcCtD
Bexarotene—Oedema—Epirubicin—testicular cancer	0.000262	0.000341	CcSEcCtD
Bexarotene—Loss of consciousness—Doxorubicin—testicular cancer	0.000261	0.00034	CcSEcCtD
Bexarotene—Infection—Epirubicin—testicular cancer	0.000261	0.000339	CcSEcCtD
Bexarotene—Cough—Doxorubicin—testicular cancer	0.000259	0.000337	CcSEcCtD
Bexarotene—Shock—Epirubicin—testicular cancer	0.000258	0.000335	CcSEcCtD
Bexarotene—Nervous system disorder—Epirubicin—testicular cancer	0.000257	0.000334	CcSEcCtD
Bexarotene—Thrombocytopenia—Epirubicin—testicular cancer	0.000257	0.000334	CcSEcCtD
Bexarotene—Hypertension—Doxorubicin—testicular cancer	0.000257	0.000334	CcSEcCtD
Bexarotene—Tachycardia—Epirubicin—testicular cancer	0.000256	0.000333	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000255	0.000332	CcSEcCtD
Bexarotene—Skin disorder—Epirubicin—testicular cancer	0.000255	0.000331	CcSEcCtD
Bexarotene—Hyperhidrosis—Epirubicin—testicular cancer	0.000254	0.000329	CcSEcCtD
Bexarotene—Insomnia—Methotrexate—testicular cancer	0.000253	0.000329	CcSEcCtD
Bexarotene—Chest pain—Doxorubicin—testicular cancer	0.000253	0.000329	CcSEcCtD
Bexarotene—Arthralgia—Doxorubicin—testicular cancer	0.000253	0.000329	CcSEcCtD
Bexarotene—Myalgia—Doxorubicin—testicular cancer	0.000253	0.000329	CcSEcCtD
Bexarotene—Anxiety—Doxorubicin—testicular cancer	0.000252	0.000328	CcSEcCtD
Bexarotene—Paraesthesia—Methotrexate—testicular cancer	0.000252	0.000327	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000251	0.000327	CcSEcCtD
Bexarotene—Discomfort—Doxorubicin—testicular cancer	0.00025	0.000325	CcSEcCtD
Bexarotene—Anorexia—Epirubicin—testicular cancer	0.00025	0.000325	CcSEcCtD
Bexarotene—Dyspnoea—Methotrexate—testicular cancer	0.00025	0.000325	CcSEcCtD
Bexarotene—Somnolence—Methotrexate—testicular cancer	0.000249	0.000324	CcSEcCtD
Bexarotene—Dry mouth—Doxorubicin—testicular cancer	0.000248	0.000322	CcSEcCtD
Bexarotene—Dyspepsia—Methotrexate—testicular cancer	0.000247	0.000321	CcSEcCtD
Bexarotene—Confusional state—Doxorubicin—testicular cancer	0.000245	0.000318	CcSEcCtD
Bexarotene—Decreased appetite—Methotrexate—testicular cancer	0.000244	0.000317	CcSEcCtD
Bexarotene—Oedema—Doxorubicin—testicular cancer	0.000243	0.000315	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000242	0.000314	CcSEcCtD
Bexarotene—Fatigue—Methotrexate—testicular cancer	0.000242	0.000314	CcSEcCtD
Bexarotene—Infection—Doxorubicin—testicular cancer	0.000241	0.000313	CcSEcCtD
Bexarotene—Pain—Methotrexate—testicular cancer	0.00024	0.000311	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000239	0.000311	CcSEcCtD
Bexarotene—Shock—Doxorubicin—testicular cancer	0.000239	0.00031	CcSEcCtD
Bexarotene—Nervous system disorder—Doxorubicin—testicular cancer	0.000238	0.000309	CcSEcCtD
Bexarotene—Thrombocytopenia—Doxorubicin—testicular cancer	0.000238	0.000309	CcSEcCtD
Bexarotene—Insomnia—Epirubicin—testicular cancer	0.000237	0.000308	CcSEcCtD
Bexarotene—Tachycardia—Doxorubicin—testicular cancer	0.000237	0.000308	CcSEcCtD
Bexarotene—Skin disorder—Doxorubicin—testicular cancer	0.000236	0.000306	CcSEcCtD
Bexarotene—Paraesthesia—Epirubicin—testicular cancer	0.000236	0.000306	CcSEcCtD
Bexarotene—Hyperhidrosis—Doxorubicin—testicular cancer	0.000235	0.000305	CcSEcCtD
Bexarotene—Dyspnoea—Epirubicin—testicular cancer	0.000234	0.000304	CcSEcCtD
Bexarotene—Somnolence—Epirubicin—testicular cancer	0.000233	0.000303	CcSEcCtD
Bexarotene—Anorexia—Doxorubicin—testicular cancer	0.000231	0.000301	CcSEcCtD
Bexarotene—Feeling abnormal—Methotrexate—testicular cancer	0.000231	0.0003	CcSEcCtD
Bexarotene—Dyspepsia—Epirubicin—testicular cancer	0.000231	0.0003	CcSEcCtD
Bexarotene—Gastrointestinal pain—Methotrexate—testicular cancer	0.000229	0.000298	CcSEcCtD
Bexarotene—Decreased appetite—Epirubicin—testicular cancer	0.000228	0.000296	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000226	0.000294	CcSEcCtD
Bexarotene—Fatigue—Epirubicin—testicular cancer	0.000226	0.000294	CcSEcCtD
Bexarotene—Constipation—Epirubicin—testicular cancer	0.000224	0.000291	CcSEcCtD
Bexarotene—Pain—Epirubicin—testicular cancer	0.000224	0.000291	CcSEcCtD
Bexarotene—Body temperature increased—Methotrexate—testicular cancer	0.000222	0.000288	CcSEcCtD
Bexarotene—Abdominal pain—Methotrexate—testicular cancer	0.000222	0.000288	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000221	0.000287	CcSEcCtD
Bexarotene—Insomnia—Doxorubicin—testicular cancer	0.000219	0.000285	CcSEcCtD
Bexarotene—Paraesthesia—Doxorubicin—testicular cancer	0.000218	0.000283	CcSEcCtD
Bexarotene—Dyspnoea—Doxorubicin—testicular cancer	0.000216	0.000281	CcSEcCtD
Bexarotene—Feeling abnormal—Epirubicin—testicular cancer	0.000216	0.000281	CcSEcCtD
Bexarotene—Somnolence—Doxorubicin—testicular cancer	0.000216	0.00028	CcSEcCtD
Bexarotene—Gastrointestinal pain—Epirubicin—testicular cancer	0.000214	0.000279	CcSEcCtD
Bexarotene—Dyspepsia—Doxorubicin—testicular cancer	0.000214	0.000278	CcSEcCtD
Bexarotene—Decreased appetite—Doxorubicin—testicular cancer	0.000211	0.000274	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.00021	0.000272	CcSEcCtD
Bexarotene—Fatigue—Doxorubicin—testicular cancer	0.000209	0.000272	CcSEcCtD
Bexarotene—Constipation—Doxorubicin—testicular cancer	0.000208	0.00027	CcSEcCtD
Bexarotene—Pain—Doxorubicin—testicular cancer	0.000208	0.00027	CcSEcCtD
Bexarotene—Body temperature increased—Epirubicin—testicular cancer	0.000207	0.000269	CcSEcCtD
Bexarotene—Abdominal pain—Epirubicin—testicular cancer	0.000207	0.000269	CcSEcCtD
Bexarotene—Hypersensitivity—Methotrexate—testicular cancer	0.000206	0.000268	CcSEcCtD
Bexarotene—Asthenia—Methotrexate—testicular cancer	0.000201	0.000261	CcSEcCtD
Bexarotene—Feeling abnormal—Doxorubicin—testicular cancer	0.0002	0.00026	CcSEcCtD
Bexarotene—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000198	0.000258	CcSEcCtD
Bexarotene—Pruritus—Methotrexate—testicular cancer	0.000198	0.000258	CcSEcCtD
Bexarotene—Hypersensitivity—Epirubicin—testicular cancer	0.000193	0.000251	CcSEcCtD
Bexarotene—Abdominal pain—Doxorubicin—testicular cancer	0.000192	0.000249	CcSEcCtD
Bexarotene—Body temperature increased—Doxorubicin—testicular cancer	0.000192	0.000249	CcSEcCtD
Bexarotene—Diarrhoea—Methotrexate—testicular cancer	0.000192	0.000249	CcSEcCtD
Bexarotene—Asthenia—Epirubicin—testicular cancer	0.000188	0.000245	CcSEcCtD
Bexarotene—Pruritus—Epirubicin—testicular cancer	0.000186	0.000241	CcSEcCtD
Bexarotene—Dizziness—Methotrexate—testicular cancer	0.000185	0.000241	CcSEcCtD
Bexarotene—Diarrhoea—Epirubicin—testicular cancer	0.000179	0.000233	CcSEcCtD
Bexarotene—Hypersensitivity—Doxorubicin—testicular cancer	0.000179	0.000232	CcSEcCtD
Bexarotene—Vomiting—Methotrexate—testicular cancer	0.000178	0.000232	CcSEcCtD
Bexarotene—Rash—Methotrexate—testicular cancer	0.000177	0.00023	CcSEcCtD
Bexarotene—Dermatitis—Methotrexate—testicular cancer	0.000177	0.000229	CcSEcCtD
Bexarotene—Headache—Methotrexate—testicular cancer	0.000176	0.000228	CcSEcCtD
Bexarotene—Asthenia—Doxorubicin—testicular cancer	0.000174	0.000226	CcSEcCtD
Bexarotene—Dizziness—Epirubicin—testicular cancer	0.000173	0.000225	CcSEcCtD
Bexarotene—Pruritus—Doxorubicin—testicular cancer	0.000172	0.000223	CcSEcCtD
Bexarotene—Vomiting—Epirubicin—testicular cancer	0.000167	0.000217	CcSEcCtD
Bexarotene—Nausea—Methotrexate—testicular cancer	0.000166	0.000216	CcSEcCtD
Bexarotene—Diarrhoea—Doxorubicin—testicular cancer	0.000166	0.000216	CcSEcCtD
Bexarotene—Rash—Epirubicin—testicular cancer	0.000165	0.000215	CcSEcCtD
Bexarotene—Dermatitis—Epirubicin—testicular cancer	0.000165	0.000215	CcSEcCtD
Bexarotene—Headache—Epirubicin—testicular cancer	0.000164	0.000214	CcSEcCtD
Bexarotene—Dizziness—Doxorubicin—testicular cancer	0.00016	0.000209	CcSEcCtD
Bexarotene—Nausea—Epirubicin—testicular cancer	0.000156	0.000202	CcSEcCtD
Bexarotene—Vomiting—Doxorubicin—testicular cancer	0.000154	0.000201	CcSEcCtD
Bexarotene—Rash—Doxorubicin—testicular cancer	0.000153	0.000199	CcSEcCtD
Bexarotene—Dermatitis—Doxorubicin—testicular cancer	0.000153	0.000199	CcSEcCtD
Bexarotene—Headache—Doxorubicin—testicular cancer	0.000152	0.000198	CcSEcCtD
Bexarotene—Nausea—Doxorubicin—testicular cancer	0.000144	0.000187	CcSEcCtD
